Bonjesta
Phase 3Small molecule
Bonjesta is one of 34 small molecule programs targeting Nausea and vomiting. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
224 competitors in Nausea and Vomiting
#DrugCompanyPhaseTrials
1Aloxi
AAvyxa
Preclinical
Bonjesta
DDuchesnay Inc.
Phase 3
Alfenta
Alnylam PharmaceuticalsPreclinical
Ramosetron
AstellasPreclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Phenergan
BBassett Healthcare
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Haldol
DDePuy Orthopaedics
Preclinical
Cytoxan
BBaxter Healthcare Corporation
Preclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Bonjesta. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- DDuchesnay Inc.